Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
102.60    -0.60 (-0.58%)
Bid:
101.80
Ask:
102.60
Spread: 0.80 (0.786%)
Market Cap: £168.21m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Interim Management Statement

17 May 2012 07:00

RNS Number : 5270D
Yule Catto & Co PLC
17 May 2012
 



 17 May 2012

 

Yule Catto & Co plc (the "Group") 

 

AGM & Interim Management Statement

 

At this morning's AGM of Yule Catto & Co plc, the international producer of speciality chemicals, Chairman Peter Wood will make the following statement which also comprises the Group's interim management statement for the period 1 January 2012 to date.

 

Profitability for the period was substantially ahead of prior year* and in line with the Board's expectations, in what has been a very challenging environment. The economic issues, particularly in Europe, have produced an environment of high raw material volatility and a general lack of business confidence.

 

In our Europe and North America segment, volumes in Q1 were 11% below what was a strong start to 2011, but 14% ahead of Q4 2011. Weakness was most evident in sales to the construction sector. Margin management has more than compensated for the lower volume levels, and together with the benefit of the planned synergies, the segment operating profit was substantially ahead of prior year.

 

In our Asia and ROW segment, the Construction and Coatings business unit showed good year on year improvement. However, in Health and Protection, demand remained subdued. Asia and ROW volumes were down 1% on Q1 2011 and 11 % ahead of Q4 2011. Margins in Health and Protection in the first half of 2011 were reasonably strong and have not been maintained at these high levels. Consequently results overall for the segment were below prior year.

 

Synergies hit an annualised run rate of £20 million as at the end of Marchand remain on track for £25M at the end of Q1 next year. This represents a £15M full year synergy benefit to 2012 operating profits compared to prior year.

 

The Group's latex expansion in Malaysia remains on track for production in the fourth quarter. This expansion will allow us to keep pace with long term demand in the high growth nitrile latex market and allow additional growth through the sale of locally manufactured SBR.

 

Net debt at the end of April was £171M, slightly up on the year end position of £164M

 

The Board also notes the current weakness of the euro which has hit 1.25 against sterling in recent days, having averaged 1.20 over the first four months of 2012, and 1.15 through 2011. The Group made a little over half of its operating profit in the euro zone in 2011. The translation effect of a one cent movement in the euro equates to approximately £0.5M of operating profit.

 

The environment remains both challenging and volatile. Against this background, the Board is pleased with the Group's financial performance year to date, and its expectations for the performance of the Group over the remainder of the year remain unchanged.

 

Note: * The Group reported an underlying proforma PBT of £96.0M for full year 2011, which included an adjustment to reflect the first quarter's pre acquisition operating profit of PolymerLatex of £13.3M and an estimated interest cost of £2.1M. Comments on PBT, operating profit performance and volumes for the period under review compared to 2011 are based on this proforma basis.

 

- Ends -

 

ENQUIRIES:

 

Yule Catto & Co plc

Tel: 01279 442791

Adrian Whitfield, Chief Executive

 

David Blackwood, Group Finance Director

 

 

 

 

MHP Communications

Tel: 020 3128 8100

Andrew Jaques

 

John Olsen

 

Ian Payne

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSLFFELEVIRLIF
Date   Source Headline
29th Sep 20227:00 amRNSTrading update
23rd Sep 20229:23 amRNSHolding(s) in Company
12th Sep 20223:27 pmRNSHolding(s) in Company
6th Sep 20228:15 amRNSHolding(s) in Company
12th Aug 20229:22 amRNSDirector/PDMR Shareholding
11th Aug 20227:00 amRNSDirector/PDMR Shareholding
9th Aug 20224:09 pmRNSHolding(s) in Company
9th Aug 20227:00 amRNSDirector/PDMR Shareholding
5th Aug 20221:20 pmRNSHolding(s) in Company
5th Aug 202211:27 amRNSDirector/PDMR Shareholding
4th Aug 20222:57 pmRNSDirector/PDMR Shareholding
4th Aug 20222:35 pmRNSDirector/PDMR Shareholding
3rd Aug 202212:29 pmRNSDirector/PDMR Shareholding
2nd Aug 20227:00 amRNSResults for the six months ended 30 June 2022
15th Jul 20222:32 pmRNSHolding(s) in Company
8th Jul 202210:23 amRNSHolding(s) in Company
1st Jul 20227:00 amRNSChief Financial Officer
30th Jun 20225:04 pmRNSHolding(s) in Company
21st Jun 20227:00 amRNSAppointment of Non-Executive Director
17th May 202212:55 pmRNSHolding(s) in Company
5th May 202212:39 pmRNSHolding(s) in Company
4th May 20224:46 pmRNSDirector/PDMR Shareholding
4th May 20227:00 amRNSAppointment of Joint Corporate Brokers
28th Apr 202212:24 pmRNSResult of AGM
28th Apr 20227:00 amRNSQ1 2022 trading update
26th Apr 20229:33 amRNSHolding(s) in Company
20th Apr 20224:13 pmRNSHolding(s) in Company
5th Apr 20224:18 pmRNSDirector/PDMR Shareholding
1st Apr 20221:34 pmRNSCompletion of adhesives acquisition
29th Mar 20223:17 pmRNSHolding(s) in Company
29th Mar 20223:14 pmRNSDirector/PDMR Shareholding
25th Mar 20222:03 pmRNSAnnual Financial Report
14th Mar 202212:50 pmRNSDirector/PDMR Shareholding
14th Mar 202212:50 pmRNSDirector/PDMR Shareholding
14th Mar 202212:48 pmRNSDirector/PDMR Shareholding
14th Mar 20229:35 amRNSHolding(s) in Company
9th Mar 202212:52 pmRNSDirector/PDMR Shareholding
8th Mar 20223:22 pmRNSDirector/PDMR Shareholding
8th Mar 20223:19 pmRNSDirector/PDMR Shareholding
3rd Mar 20227:00 amRNSPreliminary Results for the year ended 31 Dec 2021
14th Feb 20227:00 amRNSPre-close trading update
10th Feb 20223:10 pmRNSNOTIFICATION OF MAJOR HOLDINGS
22nd Dec 20215:10 pmRNSDirector/PDMR Shareholding
21st Dec 20213:09 pmRNSDirector/PDMR Shareholding
20th Dec 20213:40 pmRNSDirector/PDMR Shareholding
17th Dec 202112:29 pmRNSResults of General Meeting
15th Dec 20212:54 pmRNSDirector/PDMR Shareholding
30th Nov 20214:57 pmRNSPUBLICATION OF CIRCULAR
26th Nov 20217:00 amRNSAppointment of Chief Financial Officer
22nd Nov 202110:36 amRNSDirector Declaration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.